Magle Group today announces that the publication of its Annual Report for the financial year 2025 will be postponed.

The Annual Report, scheduled for publication on 24 June 2026, is now expected to be published on 27 June 2026. The delay is due to the ongoing audit process, which requires additional time to be completed.

The Annual General Meeting remains scheduled for 30 June 2026.

Contacts

Aaron Wong, Interim CEO, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. Today, the Group includes two operational areas. Magle Chemoswed – a contract manufacturing organization (CMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle Biopolymers A/S - a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.comand www.maglebiopolymers.com

Redeye Nordic Growth AB is the company's Certified Adviser.

Läs mer på MFN

Ämnen i artikeln


Magle Chemoswed

Senast

1,07

1 dag %

1,90%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån